Ayala Pharmaceuticals granted US FDA fast track designation for AL101 to treat recurrent or metastatic adenoid cystic carcinoma

The US FDA’s Center for Drug Evaluation and Research (Credit: The U.S. Food and Drug Administration/Wikipedia.org)